A novel small molecule PI3K inhibitor, inavolisib, has more than doubled progression-free survival when combined with CDK4/6 inhibitor palbociclib plus fulvestrant in patients with recurrent PIK3CA-mutated, HR–positive, HER2-negative advanced breast cancer [182]. Here, PIK3CA is linked to breast carcinoma.